File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: A prospective randomized pilot study

TitleIntravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: A prospective randomized pilot study
Authors
KeywordsIntracranial aneurysm
Magnesium sulfate
Subarachnoid hemorrhage
Vasospasm
Issue Date2006
Citation
Journal of Neurosurgical Anesthesiology, 2006, v. 18, n. 2, p. 142-148 How to Cite?
AbstractWe performed a randomized, double-blind, pilot study on magnesium sulfate (MgSO4) infusion for aneurysmal subarachnoid hemorrhage (SAH).Sixty patients with SAH were randomly allocated to receive either MgSO4 80 mmol/day or saline infusion for 14 days. Patients also received intravenous nimodipine. Episodes of vasospasm were treated with hypertensive and hypervolemic therapy. Neurologic status was assessed 6 months after hemorrhage using the Barthel index and Glasgow Outcome Scale. Incidences of cardiac and pulmonary complications were also recorded.Patient characteristics, severity of SAH, and surgical treatment did not differ between groups. The incidence of symptomatic vasospasm decreased from 43% in the saline group to 23% in patients receiving MgSO4 infusion, but it did not reach statistical significance, P=0.06. For patients who had transcranial Doppler-detected vasospasm, defined as mean flow velocity >120 cm/s and a Lindegaard index >3, the duration was shorter in the magnesium group compared with controls (P<0.01). There was, however, no difference between groups in functional recovery or Glasgow Outcome Scale score. The incidence of adverse events such as brain swelling, hydrocephalus, and nosocomial infection was also similar in patients receiving MgSO4 or saline.In this small pilot study, MgSO4 infusion for aneurysmal SAH is feasible. On the basis of the preliminary data, a larger study recruiting approximately 800 patients is required to test for a possible neuroprotective effect of magnesium after SAH. © 2006 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/325120
ISSN
2023 Impact Factor: 2.3
2023 SCImago Journal Rankings: 0.634
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, George K.C.-
dc.contributor.authorChan, Matthew T.V.-
dc.contributor.authorBoet, Ronald-
dc.contributor.authorPoon, Wai S.-
dc.contributor.authorGin, Tony-
dc.date.accessioned2023-02-27T07:29:54Z-
dc.date.available2023-02-27T07:29:54Z-
dc.date.issued2006-
dc.identifier.citationJournal of Neurosurgical Anesthesiology, 2006, v. 18, n. 2, p. 142-148-
dc.identifier.issn0898-4921-
dc.identifier.urihttp://hdl.handle.net/10722/325120-
dc.description.abstractWe performed a randomized, double-blind, pilot study on magnesium sulfate (MgSO4) infusion for aneurysmal subarachnoid hemorrhage (SAH).Sixty patients with SAH were randomly allocated to receive either MgSO4 80 mmol/day or saline infusion for 14 days. Patients also received intravenous nimodipine. Episodes of vasospasm were treated with hypertensive and hypervolemic therapy. Neurologic status was assessed 6 months after hemorrhage using the Barthel index and Glasgow Outcome Scale. Incidences of cardiac and pulmonary complications were also recorded.Patient characteristics, severity of SAH, and surgical treatment did not differ between groups. The incidence of symptomatic vasospasm decreased from 43% in the saline group to 23% in patients receiving MgSO4 infusion, but it did not reach statistical significance, P=0.06. For patients who had transcranial Doppler-detected vasospasm, defined as mean flow velocity >120 cm/s and a Lindegaard index >3, the duration was shorter in the magnesium group compared with controls (P<0.01). There was, however, no difference between groups in functional recovery or Glasgow Outcome Scale score. The incidence of adverse events such as brain swelling, hydrocephalus, and nosocomial infection was also similar in patients receiving MgSO4 or saline.In this small pilot study, MgSO4 infusion for aneurysmal SAH is feasible. On the basis of the preliminary data, a larger study recruiting approximately 800 patients is required to test for a possible neuroprotective effect of magnesium after SAH. © 2006 Lippincott Williams & Wilkins, Inc.-
dc.languageeng-
dc.relation.ispartofJournal of Neurosurgical Anesthesiology-
dc.subjectIntracranial aneurysm-
dc.subjectMagnesium sulfate-
dc.subjectSubarachnoid hemorrhage-
dc.subjectVasospasm-
dc.titleIntravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: A prospective randomized pilot study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/00008506-200604000-00009-
dc.identifier.pmid16628069-
dc.identifier.scopuseid_2-s2.0-33646848055-
dc.identifier.volume18-
dc.identifier.issue2-
dc.identifier.spage142-
dc.identifier.epage148-
dc.identifier.isiWOS:000237009800009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats